ABC 186 Re HEDP administered intravenously in the outpatient clinic. Methods: Patients were followed with pain diaries, records of medication, morbidity, sleep patterns, serial bone scans and a Karnofsky index. Twenty-five patients with complete records were evaluated. Patients were grouped according to the extent of bone metastases as seen in the bone scans. Results: Sixteen patients (64%) showed clinical responses of which 4 became completely painfree. Pain relief typically began 10-20 days after 186 Re HEDP was administered, while maximum benefit was normally achieved by 6 weeks. Relief of pain was maintained for 4-15 months (mean 6 months). No immediate adverse reactions were observed following the administration of 186 Re HEDP. Only a mild transient fall in platelet levels was noted, which normalized by 6 weeks. Conclusion: 186 RE HEDP appears as a safe, convenient and an effective palliative for pain secondary to bone metastases in cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.